Evidence map›Paper›PMID 26011488›Full record

ReviewNature reviews. Clinical oncology2015

Adolescent and young adult patients with cancer: a milieu of unique features.

Leonard Sender, Keri B Zabokrtsky

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03476070 (Adolescent and Young Adult Cancer Patients), which is not on this map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03476070 unknown statusnot on this mapstarted 2018, after this paper: background citation

Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)

TypeobservationalSponsorNational University of SingaporeRan2018 to 2022Enrolled236ConditionsBreast Cancer, Lymphoma, Germ Cell Tumor, Cognitive Impairment
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Leonard SenderDivision of Hematology-Oncology, Department of Medicine, School of Medicine, University of California, Irvine, 101 The City Drive South, Orange, CA 92868, USA.
Keri B ZabokrtskyHyundai Cancer Institute, Children's Hospital of Orange County, 1201 West La Veta Avenue, Orange, CA 92868, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adolescent and young adult (AYA) patients with cancer are a unique category of patients who, depending on age at time of diagnosis, might receive treatment from oncologists specializing either in the treatment of children or adults. In the USA, AYA oncology generally encompasses patients 15-39 years of age. AYA patients with cancer typically present with diseases that span the spectrum from 'paediatric' cancers (such as acute lymphoblastic leukaemia [ALL] and brain tumours) to 'adult' tumours (such as breast cancer and melanoma), as well as cancers that are largely unique to their age group (such as testicular cancer and bone tumours). Research indicates that outcomes of AYA patients with cancer are influenced not only by the treatment provided, but also by factors related to 'host' biology. In addition to the potential biological and cancer-specific differences between AYAs and other patients with cancer, AYA patients also often have disparate access to clinical trials and suffer from a lack of age-appropriate psychosocial support services and health services, which might influence survival as well as overall quality of life. In this Review, these issues are discussed, with a focus on two types of AYA cancer--ALL and melanoma--highlighting findings arising from the use of emerging technologies, such as whole-genome sequencing.

Indexed as

AdolescentAdultClinical Trials as TopicDelivery of Health CareHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityHumansImmunotherapyMelanomaMutationNeoplasm MetastasisPatient AdvocacyPatient Protection and Affordable Care ActPatient SelectionPrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID26011488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.